Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2015-12-03 Investor Presentation
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science EN
Investor Presentation Classification · 92% confidence The document is an announcement from AB Science detailing the publication of a case report regarding their drug masitinib in a medical journal. It discusses scientific rationale, ongoing clinical trials (Phase 3), and provides background on the drug and the company. This type of communication, which disseminates scientific findings, clinical trial updates, and general company/product information to the public and investors, most closely aligns with an Investor Presentation (IP) or a general scientific/research update. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal management discussion (MDA), and it is structured as an informational release about research progress, 'Investor Presentation' (IP) is the most appropriate fit among the specialized categories, as these often include detailed scientific/pipeline updates.
2015-12-03 English
AB Science FR
Investor Presentation Classification · 95% confidence The document is an announcement from AB Science dated December 2, 2015, detailing the publication of a case report regarding the drug masitinib in treating metastatic melanoma. It explicitly states that an article has been published in a peer-reviewed journal and provides citation details and a link. The document also discusses ongoing Phase 3 trials and scientific rationale. Since the core purpose of this text is to announce the publication of a specific scientific/medical report (a case study) rather than being the full financial report (10-K, IR) or a general earnings release (ER), it fits best under the category of Investor Presentation (IP) or potentially Regulatory Filings (RNS) if no better fit exists. However, given that it is a detailed update focused on clinical data and publication, 'Investor Presentation' (IP) is the most appropriate classification for this type of clinical/research update aimed at investors, even though it's structured as a press release announcing a publication. It is not a general earnings release (ER) as it focuses on clinical data, nor is it a Report Publication Announcement (RPA) because it contains substantial analysis and context beyond just stating a report is attached.
2015-12-03 French
AB Science FR
Regulatory Filings Classification · 95% confidence The document is a press release dated November 30, 2015, announcing that AB Science's Phase 3 study of masitinib for severe systemic mastocytosis met its primary and secondary endpoints. It details the study design, endpoints, target population, and provides background on the drug and the company. This type of announcement, detailing key clinical trial results immediately following a successful trial phase, is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a specific announcement of results rather than a comprehensive periodic financial report (like 10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the closest fit among the provided options for a major, immediate result announcement is 'Earnings Release' (ER), as these releases often contain operational/clinical highlights alongside financial ones, or it could be classified as a general Regulatory Filing (RNS) if it doesn't fit the specific financial reporting codes. Given the focus is purely on clinical trial success and not quarterly financials, and it's a formal announcement, it aligns best with a significant corporate update. However, since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical result announcement, it is more accurately a significant corporate event announcement. In the absence of a specific 'Clinical Trial Result Announcement' code, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases, or potentially 'ER' if we interpret 'key highlights' broadly to include major clinical milestones that drive future earnings. Given the structure and purpose (announcing a major milestone), RNS is the safest fallback, but ER often captures major operational news releases. I will lean towards RNS as the most appropriate general regulatory/corporate announcement category when a specific clinical update code is missing, as it is not a standard periodic financial report.
2015-12-02 French
AB Science EN
Earnings Release Classification · 95% confidence The document is an announcement dated November 30, 2015, titled "AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis." It details the positive outcome of a clinical trial, including primary and secondary objectives, patient population, and background information on the drug and the company. This content is characteristic of an initial release of key financial or operational results, often preceding a full report or a detailed management discussion. Since it announces the results (top-line data) rather than being the full comprehensive report (like a 10-K or IR), it fits best as an Earnings Release (ER), which covers periodical financial or operational results highlights. It is not a transcript (CT), a presentation (IP), or a formal regulatory filing like a 10-K. FY 2015
2015-12-02 English
AB Science FR
Earnings Release Classification · 95% confidence The document is an announcement dated November 30, 2015, titled "AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis." It details the positive outcome of a clinical trial, including primary and secondary objectives, patient population, and background information on the drug and the company. This content is characteristic of an initial release of key financial or operational results, often preceding a full report or a detailed management discussion. Since it announces the results (top-line data) rather than being the full comprehensive report (like a 10-K or IR), it fits best as an Earnings Release (ER), which covers periodical financial or operational results highlights. It is not a transcript (CT), a presentation (IP), or a formal regulatory filing like a 10-K. FY 2015
2015-11-30 English
AB Science FR
Earnings Release Classification · 99% confidence The document is a press release dated November 30, 2015, announcing that AB Science's Phase 3 study of masitinib for severe systemic mastocytosis met its primary and secondary endpoints. It details the study design, endpoints, target population, and provides background on the drug and the company. This type of announcement, detailing key clinical trial results immediately following a successful trial phase, is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress. Since it is a specific announcement of results rather than a comprehensive periodic financial report (like 10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the closest fit among the provided options for a major, immediate result announcement is 'Earnings Release' (ER), as these releases often contain operational/clinical highlights alongside financial ones, or it could be classified as a general Regulatory Filing (RNS) if it doesn't fit the specific financial reporting codes. Given the focus is purely on clinical trial success and not quarterly financials, and it's a formal announcement, it aligns best with a significant corporate update. However, since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical result announcement, it is more accurately a significant corporate event announcement. In the absence of a specific 'Clinical Trial Result Announcement' code, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases, or potentially 'ER' if we interpret 'key highlights' broadly to include major clinical milestones that drive future earnings. Given the structure and purpose (announcing a major milestone), RNS is the safest fallback, but ER often captures major operational news releases. I will lean towards RNS as the most appropriate general regulatory/corporate announcement category when a specific clinical update code is missing, as it is not a standard periodic financial report. FY 2015
2015-11-30 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.